Cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and the exposure of particular phagocytosis signaling molecules on the cell surface are just a few of the distinctive morphological and biochemical features of the cell death process known as apoptosis. Apoptosis-initiated cell death is distinct from necrosis-induced cell death. Apoptotic death, in contrast, is silent and orderly. Necrotic cells are typically recognized as a danger signal by the immune system, which causes inflammation.
There are two main methods for inducing apoptotic cell death: The intrinsic pathway, also known as the Bcl-2-regulated or mitochondrial pathway, is strictly regulated by the BCL-2 family of proteins and is activated by a variety of developmental cues or cytotoxic insults, such as viral infection, DNA damage, and growth-factor deprivation.The tumor necrosis factor (TNF) receptor family members, such as Fas or TNF receptor-1 (TNFR1), which contain an intracellular death domain and can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface, are what initiate the extrinsic or death-receptor pathway. Without the involvement of the BCL-2 family, this recruitment results in the subsequent activation of downstream (effector) caspases like caspase-3, -6, or -7.
Numerous human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome), may be influenced by changes in cell survival, according to studies. Some of these diseases may not progress naturally unless specific therapies that change the apoptotic threshold are used.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V56250 | Sildenafil citrate-d8 (UK-92480 citrate-d8) | 1215071-03-6 | Sildenafil (citrate)-d8 is the deuterium labelled form of Sildenafil citrate. |
|
V52565 | Sildenafil-d8 (UK-92480-d8) | 951385-68-5 | Sildenafil-d8 is the deuterium labelled form of Sildenafil. |
|
V34744 | Silybin (Silybin; Silibinin) | 802918-57-6 | Silybin is a flavin oligosaccharide extracted from Silybum marianum seeds. |
|
V56400 | Simvastatin-d11 (MK 733-d11) | 1002347-74-1 | Simvastatin-d11 is the deuterium labelled form of Simvastatin. |
|
V52559 | Simvastatin-d3 (MK 733-d3) | 1002347-61-6 | Simvastatin-d3 is the deuterium labelled form of Simvastatin. |
|
V52558 | Simvastatin-d6 (MK 733-d6) | 1002347-71-8 | Simvastatin-d6 (MK 733-d6) is the deuterated form of Simvastatin. |
|
V34688 | Sincalide ammonium (Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium) | 70706-98-8 | Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a fast-acting amino acid (AA) peptide hormone analog of cholecystokinin (CCK) that is administered intravenously during cholecystography. |
|
V36573 | Sirt1/2-IN-2 | 670267-73-9 | Sirt1/2-IN-2 (compound hsa55) is a dual (bifunctional) inhibitor of SIRT1/2 with IC50 of 1.8 μM (SIRT1) and 2.4 μM (SIRT2), respectively. |
|
V36395 | Sirt1/2-IN-3 | 301313-42-8 | Sirt1/2-IN-3 (compound PS9) is a dual (bifunctional) inhibitor of SIRT1/2 with IC50 of 1.4 μM (SIRT1) and 2.0 μM (SIRT2), respectively. |
|
V36332 | SIRT6 activator 12q | 2601734-99-8 | SIRT6 activator 12q is a specific and orally bioactive SIRT6 activator with IC50s of 171.20, >200, >200, >200 and 0.58 μM for SIRT1, SIRT2, SIRT3, SIRT5 and SIRT6 respectively. |
|
V35932 | SKI-I | 306301-68-8 | SKI-I is a potent and specific inhibitor of human sphingosine kinase (SK), inhibiting ST-hSK with IC50 of 1.2 μM. |
|
V76506 | SLC7A11-IN-1 | SLC7A11-IN-1 is a potent SLC7A11 inhibitor. | |
|
V34759 | SLF | 195513-96-3 | SLF is a synthetic ligand for FK506 binding protein (FKBP), with an affinity of 3.1 μM for FKBP51 and IC50 of 2.6 μM for FKBP12. |
|
V34764 | SLF TFA | 2378802-47-0 | SLF TFA is a synthetic ligand for FK506 binding protein (FKBP), with an affinity of 3.1 μM for FKBP51 and IC50 of 2.6 μM for FKBP12. |
|
V35692 | SLMP53-2 | 1826116-38-4 | SLMP53-2 is a mutated p53 reactivator. |
|
V3014 | SMIP004 | 143360-00-3 | SMIP004, aN-(4-butyl-2-methyl-phenyl) acetamide, is a novel specific inducer of cancer-cell selective apoptosis of human prostate cancer cells. |
|
V54922 | Sonrotoclax (BGB 11417) | 2383086-06-2 | Sonrotoclax is an orally bioavailable Bcl2 inhibitor. |
|
V52674 | Sorafenib-13C,d3 | 1210608-86-8 | Sorafenib-13C,d3 is a 13C- and deuterated-labeled version of Sorafenib. |
|
V35269 | Sotevtamab (16B5; AB-16B5) | 2411526-47-9 | Sotevtamab (16B5) is an anti-clusterin monoclonal antibody (mAb). |
|
V35258 | SRS16-86 | 1793052-96-6 | SRS16-86 is a potent inhibitor of ferroptosis. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
